# Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

> **NCT05918211** · PHASE3 · RECRUITING · sponsor: **Mezzion Pharma Co. Ltd** · enrollment: 436 (estimated)

## Conditions studied

- Single Ventricle Heart Disease

## Interventions

- **DRUG:** Udenafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05918211
- **Lead sponsor:** Mezzion Pharma Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2025-10-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 436 (ESTIMATED)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918211, "Fontan Udenafil Exercise Longitudinal Assessment Trial - 2". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05918211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*